Cagrilintide + Semaglutide (CagriSema) (10mg) Dosage Protocol
CagriSema combines cagrilintide (amylin analog) with semaglutide (GLP-1 agonist) for enhanced weight management. Phase 3 trials show superior efficacy compared to either component alone.
Add 2.0 mL bacteriostatic water → 5 mg/mL total
Once weekly injection, titrated dosing
Dose based on titration schedule
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 0.6/0.25 mg weekly | Cagri/Sema starting dose |
| Weeks 5-8 | 1.2/0.5 mg weekly | First escalation |
| Weeks 9+ | 2.4/2.4 mg weekly | Target maintenance dose |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Cagrilintide activates amylin receptors (satiety, gastric emptying) while semaglutide activates GLP-1 receptors (appetite suppression, glycemic control). The combination provides complementary mechanisms for enhanced weight loss.
- Superior weight loss vs monotherapy
- Dual mechanism of action
- Once weekly convenience
- Phase 3 trial data available
- Novo Nordisk CagriSema Phase 3 trials
- Amylin and GLP-1 combination research
- REDEFINE clinical trial program
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Slow titration essential for tolerability
- •Investigational combination
- •Slow titration reduces GI side effects
- •Nausea common during dose escalation
- •Being developed by Novo Nordisk
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.